Your browser doesn't support javascript.
loading
Tetrameric glycoprotein complex gH/gL/gQ1/gQ2 is a promising vaccine candidate for human herpesvirus 6B.
Wang, Bochao; Hara, Kouichi; Kawabata, Akiko; Nishimura, Mitsuhiro; Wakata, Aika; Tjan, Lidya Handayani; Poetranto, Anna Lystia; Yamamoto, Chisato; Haseda, Yasunari; Aoshi, Taiki; Munakata, Lisa; Suzuki, Ryo; Komatsu, Masato; Tsukamoto, Ryuko; Itoh, Tomoo; Nishigori, Chikako; Saito, Yasuyuki; Matozaki, Takashi; Mori, Yasuko.
Afiliação
  • Wang B; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Hara K; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Kawabata A; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Nishimura M; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Wakata A; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Tjan LH; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Poetranto AL; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Yamamoto C; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Haseda Y; Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Aoshi T; Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Munakata L; BIKEN Center for Innovative Vaccine Research and Development, The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Suzuki R; Laboratory of Drug and Gene Delivery Research, Faculty of Pharma-Science, Teikyo University, Itabashi-ku, Tokyo, Japan.
  • Komatsu M; Laboratory of Drug and Gene Delivery Research, Faculty of Pharma-Science, Teikyo University, Itabashi-ku, Tokyo, Japan.
  • Tsukamoto R; Department of Diagnostic Pathology, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Itoh T; Department of Diagnostic Pathology, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Nishigori C; Department of Diagnostic Pathology, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Saito Y; Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Matozaki T; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Mori Y; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
PLoS Pathog ; 16(7): e1008609, 2020 07.
Article em En | MEDLINE | ID: mdl-32702057
Primary infection of human herpesvirus 6B (HHV-6B) occurs in infants after the decline of maternal immunity and causes exanthema subitum accompanied by a high fever, and it occasionally develops into encephalitis resulting in neurological sequelae. There is no effective prophylaxis for HHV-6B, and its development is urgently needed. The glycoprotein complex gH/gL/gQ1/gQ2 (called 'tetramer of HHV-6B') on the virion surface is a viral ligand for its cellular receptor human CD134, and their interaction is thus essential for virus entry into the cells. Herein we examined the potency of the tetramer as a vaccine candidate against HHV-6B. We designed a soluble form of the tetramer by replacing the transmembrane domain of gH with a cleavable tag, and the tetramer was expressed by a mammalian cell expression system. The expressed recombinant tetramer is capable of binding to hCD134. The tetramer was purified to homogeneity and then administered to mice with aluminum hydrogel adjuvant and/or CpG oligodeoxynucleotide adjuvant. After several immunizations, humoral and cellular immunity for HHV-6B was induced in the mice. These results suggest that the tetramer together with an adjuvant could be a promising candidate HHV-6B vaccine.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas do Envelope Viral / Vacinas contra Herpesvirus / Exantema Súbito Limite: Animals / Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas do Envelope Viral / Vacinas contra Herpesvirus / Exantema Súbito Limite: Animals / Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão
...